Staidson (Beijing) BioPharmaceuticals (300204) Fundamentals 2026 — Revenue Analysis | SniperIQ
Staidson (Beijing) BioPharmaceuticals (300204) is a CN-listed Healthcare company in Biotechnology with a market capitalization of ¥12.0B, trading at ¥25.07 on the SHZ. This SniperIQ fundamentals page covers Staidson (Beijing) BioPharmaceuticals's valuation, profitability (net margin -41.1%), revenue (¥220M in FY2025), balance-sheet quality, and AI signal context — from live market data, research only.
Full research coverage
- 8-Quarter Revenue & Margin Trend
- Debt Maturity & Coverage
- Peer Valuation Comparison
- Free Cash Flow & Owner Earnings
- AI Signal + Institutional Flow
- DCF Valuation Model
Frequently Asked Questions
What is Staidson (Beijing) BioPharmaceuticals's market cap?
Staidson (Beijing) BioPharmaceuticals (300204) has a market capitalization of approximately ¥12.0B, trading at ¥25.07 on the SHZ. Market cap moves with the live share price.
What is Staidson (Beijing) BioPharmaceuticals's P/E ratio?
Staidson (Beijing) BioPharmaceuticals's trailing twelve-month P/E ratio is not meaningful (negative or nil earnings), with a price-to-book (P/B) of 14.8x. Valuation multiples are best compared with Healthcare sector peers rather than read in isolation.
How profitable is Staidson (Beijing) BioPharmaceuticals?
Staidson (Beijing) BioPharmaceuticals runs a net profit margin of -41.1%, a gross margin of 77.2%, and an operating margin of -44.0%. Margins and ROE indicate how efficiently the business converts sales into profit and shareholder returns.
How much revenue does Staidson (Beijing) BioPharmaceuticals generate?
Staidson (Beijing) BioPharmaceuticals reported revenue of ¥220M for fiscal year 2025, with net income of -¥78M and earnings per share (EPS) of -0.16. SniperIQ tracks the full 8-quarter revenue and margin trend on the research dashboard.
Does Staidson (Beijing) BioPharmaceuticals pay a dividend?
Staidson (Beijing) BioPharmaceuticals does not currently show a material trailing dividend yield; it is positioned more as a total-return name. Always confirm the latest dividend policy in the company's filings.
Is Staidson (Beijing) BioPharmaceuticals financially healthy?
Staidson (Beijing) BioPharmaceuticals carries a debt-to-equity ratio of 0.15x and a current ratio of 2.00x, with a market beta of 0.44. Lower leverage and a current ratio above 1.0 generally signal a stronger balance sheet.
Is Staidson (Beijing) BioPharmaceuticals a good stock to buy in 2026?
SniperIQ provides research-only market intelligence, not personalised financial advice or a buy/sell call. For Staidson (Beijing) BioPharmaceuticals (300204) the key facts are: market cap ¥12.0B, revenue ¥220M, 52-week range 18.98-66.66. Weigh valuation, profitability, growth, and balance-sheet strength against Healthcare peers and form your own view.
Track Staidson (Beijing) BioPharmaceuticals's full fundamentals live
Get Staidson (Beijing) BioPharmaceuticals's 8-quarter revenue and margin trend, peer comparison, DCF model, and AI signal on the SniperIQ research dashboard.